Technology Bundle ID: TAB-2769

CD40 Ligand: Adjuvant for Enhanced Immune Response to Respiratory Syncytial Virus

Request More Info
Primary Inventors: 
Ralph Tripp (CDC)
Larry Anderson (CDC), Michael Brown (CDC)
Development Stage: 
Pre-clinical (in vivo)
Development Status: 
  • In vitro data available
  • In vivo data available (animal)
Institute or Center: 

CDC researchers have developed methods and adjuvants for enhancing a subject's immune response to respiratory syncytial virus (RSV) by inclusion of a CD40 binding protein. RSV has long been recognized as a major respiratory tract pathogen of infants, as well as older children and the elderly. Established, successful methods for preventing RSV are currently unavailable. CD40 ligand (CD40L, also known as CD154) is an important costimulatory molecule found on the T-cell and is critical for the development of immunity. CD40L may provide a novel adjuvant to enhance cytokine and antibody response to RSV, directing a subject's immune response further towards Th1-mediated outcomes rather than a less effective Th2-type response. This Th2-type response has been previously suggested as the cause of previous live-RSV vaccine failures. This technology, appropriately developed and integrated into an RSV vaccination agenda, may be useful in improving the efficacy of current or future RSV vaccines.

  • Improvements to current RSV vaccines
  • Public health vaccination programs
  • Enhancing antibody response and T-cell costimulation for targeted immunogenic outcomes
  • Pharma development programs focusing on care for neonates, children and the elderly
  • Increased expression of Th1-type cytokines and antibody production
  • Enhanced CD40 costimulation
  • May overcome prior live-RSV vaccine issues (which generated a primarily Th2-type immune response) by steering post-vaccination immunity further towards a preferred Th1-type (IL-2 and IFN-gamma) response, enhancing virus clearance in vivo


PCT Application PCT/US01/003584
Filed on 2001-02-02
US Application 60/179,905
Filed on 2000-02-02
US Pat 7,371,392

Issued 2008-05-13
US Pat 8,354,115

Issued 2013-01-15

Various international patents issued


Tripp RA, et al.
PMID 10820273


Feb 6, 2014

Data Source: